Advertisement
COO vs GMED
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COO is a Hold and GMED is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COO’s FA Score shows that 0 FA rating(s) are green whileGMED’s FA Score has 0 green FA rating(s).
- COO’s FA Score: 0 green, 5 red.
- GMED’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COO’s TA Score shows that 4 TA indicator(s) are bullish while GMED’s TA Score has 6 bullish TA indicator(s).
- COO’s TA Score: 4 bullish, 4 bearish.
- GMED’s TA Score: 6 bullish, 4 bearish.
Price Growth
COO (@Pharmaceuticals: Other) experienced а -0.89% price change this week, while GMED (@Medical/Nursing Services) price change was -2.04% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.90%. For the same industry, the average monthly price growth was +2.44%, and the average quarterly price growth was +10.11%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.65%. For the same industry, the average monthly price growth was -6.36%, and the average quarterly price growth was +11.06%.
Reported Earning Dates
COO is expected to report earnings on Dec 04, 2025.
GMED is expected to report earnings on Feb 19, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-0.90% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-1.65% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| COO | GMED | COO / GMED | |
| Capitalization | 15B | 11B | 136% |
| EBITDA | 1.09B | 620M | 176% |
| Gain YTD | -22.648 | -0.520 | 4,356% |
| P/E Ratio | 37.00 | 26.63 | 139% |
| Revenue | 4.05B | 2.63B | 154% |
| Total Cash | 125M | 229M | 55% |
| Total Debt | 2.48B | 121M | 2,048% |
COO | GMED | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 4 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 56 | |
SMR RATING 1..100 | 81 | 72 | |
PRICE GROWTH RATING 1..100 | 61 | 38 | |
P/E GROWTH RATING 1..100 | 85 | 99 | |
SEASONALITY SCORE 1..100 | n/a | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GMED's Valuation (76) in the Medical Specialties industry is in the same range as COO (77). This means that GMED’s stock grew similarly to COO’s over the last 12 months.
GMED's Profit vs Risk Rating (56) in the Medical Specialties industry is somewhat better than the same rating for COO (100). This means that GMED’s stock grew somewhat faster than COO’s over the last 12 months.
GMED's SMR Rating (72) in the Medical Specialties industry is in the same range as COO (81). This means that GMED’s stock grew similarly to COO’s over the last 12 months.
GMED's Price Growth Rating (38) in the Medical Specialties industry is in the same range as COO (61). This means that GMED’s stock grew similarly to COO’s over the last 12 months.
COO's P/E Growth Rating (85) in the Medical Specialties industry is in the same range as GMED (99). This means that COO’s stock grew similarly to GMED’s over the last 12 months.
| COO | GMED | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 76% |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 58% |
| Momentum ODDS (%) | 2 days ago 64% | 2 days ago 68% |
| MACD ODDS (%) | 2 days ago 75% | 2 days ago 70% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 58% |
| TrendMonth ODDS (%) | 2 days ago 61% | 2 days ago 60% |
| Advances ODDS (%) | 10 days ago 59% | 12 days ago 65% |
| Declines ODDS (%) | 2 days ago 60% | 4 days ago 59% |
| BollingerBands ODDS (%) | 3 days ago 75% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 51% | 2 days ago 50% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CMCI | 25.98 | N/A | N/A |
| VanEck® CMCI Commodity Strategy ETF | |||
| BSMQ | 23.65 | N/A | -0.02% |
| Invesco BulletShares 2026 Muncpl Bd ETF | |||
| GLDI | 168.72 | -0.09 | -0.05% |
| UBS ETRACS Gold Shares Covered Call ETN | |||
| QUS | 168.35 | -1.92 | -1.13% |
| Stt Strt® SPDR® MSCI USA StratFacs ETF | |||
| HGRO | 27.24 | -0.42 | -1.52% |
| Hedgeye Quality Growth ETF | |||